Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors

Michalis Liontos; Evangelos Terpos; Christos Markellos; Flora Zagouri; Alexandros Briasoulis; Ioanna Katsiana; Efthymia Skafida; Oraianthi Fiste; Elena Kunadis; Angeliki Andrikopoulou; Maria Kaparelou; Konstantinos Koutsoukos; Maria Gavriatopoulou; Efstathios Kastritis; Ioannis P. Trougakos; Meletios-Athanasios Dimopoulos

doi:10.3390/vaccines9101148

Vaccines (Oct 2021)

Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors

Michalis Liontos,
Evangelos Terpos,
Christos Markellos,
Flora Zagouri,
Alexandros Briasoulis,
Ioanna Katsiana,
Efthymia Skafida,
Oraianthi Fiste,
Elena Kunadis,
Angeliki Andrikopoulou,
Maria Kaparelou,
Konstantinos Koutsoukos,
Maria Gavriatopoulou,
Efstathios Kastritis,
Ioannis P. Trougakos,
Meletios-Athanasios Dimopoulos

Affiliations

Michalis Liontos: Department of Clinical Therapeutics, School of Medicine, Alexandra General Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece
Evangelos Terpos: Department of Clinical Therapeutics, School of Medicine, Alexandra General Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece
Christos Markellos: Department of Clinical Therapeutics, School of Medicine, Alexandra General Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece
Flora Zagouri: Department of Clinical Therapeutics, School of Medicine, Alexandra General Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece
Alexandros Briasoulis: Department of Clinical Therapeutics, School of Medicine, Alexandra General Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece
Ioanna Katsiana: Department of Clinical Therapeutics, School of Medicine, Alexandra General Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece
Efthymia Skafida: Department of Clinical Therapeutics, School of Medicine, Alexandra General Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece
Oraianthi Fiste: Department of Clinical Therapeutics, School of Medicine, Alexandra General Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece
Elena Kunadis: Department of Clinical Therapeutics, School of Medicine, Alexandra General Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece
Angeliki Andrikopoulou: Department of Clinical Therapeutics, School of Medicine, Alexandra General Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece
Maria Kaparelou: Department of Clinical Therapeutics, School of Medicine, Alexandra General Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece
Konstantinos Koutsoukos: Department of Clinical Therapeutics, School of Medicine, Alexandra General Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece
Maria Gavriatopoulou: Department of Clinical Therapeutics, School of Medicine, Alexandra General Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece
Efstathios Kastritis: Department of Clinical Therapeutics, School of Medicine, Alexandra General Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece
Ioannis P. Trougakos: Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens, 11528 Athens, Greece
Meletios-Athanasios Dimopoulos: Department of Clinical Therapeutics, School of Medicine, Alexandra General Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece

DOI: https://doi.org/10.3390/vaccines9101148
Journal volume & issue: Vol. 9, no. 10
p. 1148

Abstract

Read online

Objective: Vaccination for SARS-CoV-2 provides significant protection against the infection in the general population. However, limited data exist for cancer patients under systemic therapy. Methods: In this cohort, we prospectively enrolled cancer patients treated with PARPi as well as healthy volunteers in order to study the kinetics of anti-SARS-CoV-2 antibodies (NAbs) after COVID-19 vaccination. Baseline demographics, co-morbidities, and NAb levels were compared between the two groups. Results: The results of the cohort of 36 patients receiving PARP inhibitors are presented here. Despite no new safety issues being noticed, their levels of SARS-CoV-2 neutralizing antibodies were significantly lower in comparison to matched healthy volunteers up to day 30 after the second dose. Conclusions: These results suggest that maintaining precautions against COVID-19 is essential for cancer patients and should be taken into consideration for the patients under treatment, while further exploration is needed to reduce the uncertainty of SARS-CoV-2 immunity among cancer patients under treatment.

Published in Vaccines

ISSN: 2076-393X (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Medicine
Website: http://www.mdpi.com/journal/vaccines

About the journal

Abstract

Keywords